Antimicrobial, anti-biofilm, and anti-proliferative activities of lipopeptide biosurfactant produced by Acinetobacter junii B6

Microb Pathog. 2020 Jan:138:103806. doi: 10.1016/j.micpath.2019.103806. Epub 2019 Oct 17.

Abstract

Lipopeptide biosurfactants (LPBs) are amphiphilic compounds produced by microorganisms exhibiting various biological activities. The main aim of the present study was to assess the in vitro antimicrobial, anti-biofilm, and cytotoxic effects of LPB produced by Acinetobacter junii (AjL). We determined AjL minimum inhibitory concentration (MIC) against both Gram-positive and Gram-negative bacteria as well as two fungal strains. Also, the anti-biofilm activity of AjL against the biofilm produced by clinically isolated bacterial strains was investigated. The AjL non-selectively showed activity against both Gram-positive and Gram-negative bacterial strains. The obtained results of the present study exhibited that the AjL in concentrations nearly below critical micelle concentration (CMC) has an effective antibacterial activity. It was found that the MIC values of AjL were lower than standard antifungal and it exhibited nearly 100% inhibition against Candida utilis. The attained results of the biofilm formation revealed that AjL disrupted the biofilm of Proteus mirabilis, Staphylococcus aureus, and Pseudomonas aeruginosa at 1250 μg/ml and 2500 μg/ml concentrations. The attained results of cytotoxic effect (determined by WST-1 assay) of the AjL revealed IC50 of 7.8 ± 0.4 mg/ml, 2.4 ± 0.5 mg/ml, and 5.7 ± 0.1 mg/ml, against U87, KB, and HUVEC cell lines, respectively. The results indicated that AjL has a potential application in the relatively new field of biomedicine.

Keywords: Acinetobacter junii; Anti-biofilm; Anti-proliferative; Antimicrobial; Biosurfactant; Lipopeptide.

MeSH terms

  • Acinetobacter / metabolism*
  • Antimicrobial Cationic Peptides / biosynthesis*
  • Bacteria / drug effects
  • Biofilms / drug effects
  • Cell Survival / drug effects
  • Dose-Response Relationship, Drug
  • Fungi / drug effects
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Humans
  • Lipopeptides / biosynthesis*
  • Microbial Sensitivity Tests
  • Staphylococcus aureus / drug effects
  • Surface-Active Agents / metabolism*

Substances

  • Antimicrobial Cationic Peptides
  • Lipopeptides
  • Surface-Active Agents

Supplementary concepts

  • Acinetobacter junii